youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
AMGN:NASDAQ
Amgen Inc
$466.01
arrow_upward
+1.15%(+5.28) 1D
$466.01
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 30, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN...
Open
$470.15
High
$475.64
Low
$465.33
Mkt. cap
251.94B
Avg. vol.
2.92M
Volume
3.29M
Dividend
2.16%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
28.94
52-wk high
$475.64
52-wk low
$288.00
EPS
$16.10
Beta
0.41
Shares outstanding
540.63M
No. of employees
32K
Open
$470.15
High
$475.64
Low
$465.33
Mkt. cap
251.94B
Avg. vol.
2.92M
Volume
3.29M
Dividend
2.16%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
28.94
52-wk high
$475.64
52-wk low
$288.00
EPS
$16.10
Beta
0.41
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
News Corp
·
4 hours ago
Big Homes, Big Loans
Seeking Alpha
·
11 hours ago
Amgen: I Have Clear Doubts About This Company Headed Into Earnings - Earnings Preview
News Corp
·
13 hours ago
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
Zacks
·
13 hours ago
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
Founded1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com
Analyst ratings
Based on 27 analysts giving stock ratings to AMGN in the past 3 months
Buy
Buy
9
Hold
16
Sell
2
12-month forecast
Based on 27 Wall Street analysts offering 12 month price targets for AMGN in the last 3 months.
Highest
Current $466.01
$500.00 (+7.29%)
Average
$406.71 (-12.73%)
Lowest
$230.00 (-50.64%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Luca Issi RBC Capital | Buy | Maintained | $430.00 | -7.7% | 10/27/2026 |
Mohit Bansal Wells Fargo | Hold | Maintained | $430.00 | -7.7% | 10/27/2026 |
Louise Chen Scotiabank | Buy | Maintained | $500.00 | +7.3% | 10/26/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $481.00 | +3.2% | 10/25/2026 |
Yaron Werber TD Cowen | Buy | Reiterated | $452.00 | -3% | 10/26/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $457.00 | -1.9% | 10/26/2026 |
Courtney Breen Bernstein | Hold | Maintained | $345.00 | -26% | 10/25/2026 |
Tazeen Ahmad Bank of America Securities | Sell | Maintained | $328.00 | -29.6% | 10/26/2026 |
Geoff Meacham Citi | Hold | Maintained | $405.00 | -13.1% | 10/27/2026 |
Emily Field Barclays | Hold | Maintained | $400.00 | -14.2% | 10/26/2026 |
Michael Yee UBS | Buy | Maintained | $470.00 | +0.9% | 10/24/2026 |
Jay Olson Oppenheimer | Buy | Reiterated | $480.00 | +3% | 10/23/2026 |
Vamil Divan Guggenheim | Hold | Maintained | $378.00 | -18.9% | 10/12/2026 |
Evan Seigerman BMO Capital | Hold | Maintained | $415.00 | -10.9% | 10/12/2026 |
Carter Gould Cantor Fitzgerald | Hold | Reiterated | $440.00 | -5.6% | 10/08/2026 |
Gregory Renza Truist Financial | Hold | Maintained | $380.00 | -18.5% | 10/07/2026 |
Terence Flynn Morgan Stanley | Hold | Maintained | $359.00 | -23% | 10/07/2026 |
Christopher Raymond Raymond James | Hold | Maintained | - | - | 09/24/2026 |
Unknown Analyst Leerink Partners | Hold | Maintained | - | - | 09/23/2026 |
Unknown Analyst Jefferies | Hold | Maintained | $410.00 | -12% | 09/23/2026 |
Gary Nachman Canaccord Genuity | Hold | Maintained | $384.00 | -17.6% | 09/23/2026 |
Matt Phipps William Blair | Buy | Maintained | - | - | 09/22/2026 |
Morten Herholdt HSBC | Hold | Downgraded | $425.00 | -8.8% | 09/09/2026 |
Jasper Hellweg Argus Research | Buy | Reiterated | $460.00 | -1.3% | 08/18/2026 |
Salim Syed Mizuho Securities | Hold | Maintained | $352.00 | -24.5% | 08/17/2026 |
Chris Schott J.P. Morgan | Hold | Maintained | $350.00 | -24.9% | 08/06/2026 |
Brian Skorney Robert W. Baird | Sell | Maintained | $230.00 | -50.6% | 08/05/2026 |
Ilya Zubkov Freedom Capital Markets | Buy | Upgraded | $375.00 | -19.5% | 05/07/2026 |
Hans Engel Erste Group | Hold | Downgraded | - | - | 05/05/2026 |
Unknown Analyst Raymond James | Hold | Reiterated | - | - | 05/01/2026 |
Umer Raffat Evercore ISI | Buy | Maintained | - | - | 05/01/2026 |
Unknown Analyst J.P. Morgan | Hold | Initiated | $300.00 | -35.6% | 05/01/2026 |
Unknown Analyst Canaccord Genuity | Hold | Initiated | $366.00 | -21.5% | 04/21/2026 |
Akash Tewari Jefferies | Hold | Initiated | $350.00 | -24.9% | 03/10/2026 |
Unknown Analyst Argus Research | Buy | Maintained | $400.00 | -14.2% | 02/06/2026 |
Next call in 4 days
Tue, Nov 3, 11:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $5.79
Revenue / Est. (USD)
- / 10.08B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 9.56B | 9.87B | 8.62B | 10.05B |
Cost of goods sold | 2.74B | 2.68B | 2.50B | 2.75B |
Cost of revenue | 2.74B | 2.68B | 2.50B | 2.75B |
Research and development expenses | 1.90B | 2.14B | 1.72B | 1.87B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.72B | 1.95B | 1.60B | 1.74B |
Operating expense | 3.55B | 4.18B | 3.21B | 3.73B |
Total operating expenses | 6.29B | 6.85B | 5.70B | 6.48B |
Operating income | 3.26B | 3.01B | 2.91B | 3.57B |
Other non operating income | 181.00M | 143.00M | 192.00M | 145.00M |
EBT including unusual items | 3.92B | 1.51B | 2.08B | 2.77B |
EBT excluding unusual items | 2.72B | 2.51B | 2.37B | 3.06B |
Income tax expense | 705.00M | 181.00M | 265.00M | 393.00M |
Effective tax rate | 17.98% | 11.96% | 12.72% | 14.20% |
Other operating expenses | -71.00M | 82.00M | -113.00M | 116.00M |
Net income | 3.22B | 1.33B | 1.82B | 2.38B |
Net profit margin | 33.65% | 13.51% | 21.11% | 23.62% |
Earnings per share | 5.64 | 5.29 | 5.15 | 6.29 |
Interest and investment income | - | 408.00M | - | - |
Interest expense | -685.00M | -1.06B | -657.00M | -673.00M |
Net interest expenses | -685.00M | -653.00M | -657.00M | -673.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 4.57B | 4.02B | 4.03B | 4.69B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events